GMP Requirements for Certificates of Analysis (CoA)
Recommendation
Tuesday, 4 February 2025 9 .00 - 17.00 h
Establishment, Use and Maintenance of Analytical Reference Substances
At times of outsourcing and globalisation, the significance of Certificates of Analysis (CoA) is growing. Ultimately, the user of such certificates has to rely on their accuracy and completeness.
There are CoAs for excipients, APIs, packaging materials and finished products. A closer look at the guidelines shows that there are a few regulatory requirements which are often unknown. Requirements can be found in the following sets of rules:
- EU GMP Guide Part I (Chapter 4 and Chapter 6)
- EU GMP Guide Part II - Section 11.4
- EMA Guideline on batch certification (Internationally harmonised Requirements for Batch Certification)
- WHO Annex 10 - Model Certificate of Analysis
- USP General Chapter <1080> Bulk Pharmaceutical Excipients - CoA
- IPEC CoA Guide for Pharmaceutical Excipients
According to the EU GMP Guide Part I, certificates of analysis provide an overview of test results obtained from a product or a material. This also includes the assessment of compliance with the specification determined.
Section 11.4 of the EU GMP Guide Part II on certificates of analysis requires an authentic certificate of analysis for each batch of an intermediate or API. Among other things, this certificate should contain the following information:
- Name of the intermediate or API
- Batch number
- Release date
- Expiry date
- List of the tests performed including acceptance limits
- Numerical results
- Dated signature by authorised personnel
- Name of the company
- or Name of the laboratory
You can find specific requirements regarding CoAs in these GMP guidelines. This is a difference to other quality guidelines like e.g. ISO 9001, where you don´t have this concretisation.
Related GMP News
21.11.2024New GMP Journal Article on Analytical Instrument Qualification and System Validation
21.11.2024FDA Warns Chinese OTC Drug Manufacturer Following Review of Records
21.11.2024The Interplay of Data Governance, Integrity, and Quality in Pharmaceutical Analysis
20.11.2024USP-NF Stimuli Article on Stability of Compounded Preparations
07.11.2024FDA Publishes Guideline on Bioequivalence for Immediate-Release Solid Oral Dosage Forms